利格列汀联合阿卡波糖治疗老年糖尿病的疗效及安全性分析
2018-12-10王福涛
王福涛
[摘要] 目的 探讨利格列汀联合阿卡波糖治疗老年糖尿病的疗效及安全性。方法 选取该科2017年2月—2018年2月收治的老年糖尿病患者134例,随机分为两组各67例,对照组给予阿卡波糖,观察组给予利格列汀联合阿卡波糖,比较疗效。结果 观察组FPG、2 hPG、HbA1c明显低于对照组(P<0.05);观察组不良反应发生率为7.5%,明显低于对照组13.4%(P<0.05)。结论 老年糖尿病患者采用利格列汀联合阿卡波糖治疗,可有效控制血糖水平,降低低血糖等不良反应的发生,值得应用。
[关键词] 利格列汀;阿卡波糖;老年糖尿病
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)07(a)-0090-02
Analysis of Curative Effect and Safety of Trajenta and Acarbose in Treatment of Senile Diabetes
WANG Fu-tao
Endocrine Department, Changchun Central Hospital, Changchun, Jilin Province, 130000 China
[Abstract] Objective To study the curative effect and safety of trajenta and acarbose in treatment of senile diabetes. Methods 134 cases of senile diabetes patients admitted and treated in our hospital from February 2017 to February 2018 were selected and randomly divided into two groups with 67 cases in each, the control group were treated with acarbose, while the observation group were treated with trajenta and acarbose, and the curative effect was compared between the two groups. Results The FPG, 2 hPG, HbA1c in the observation group were obviously lower than those in the control group(P<0.05), and the incidence rate of adverse reactions in the observation group was obviously lower than that in the control group(7.5% vs 13.4%)(P<0.05). Conclusion The trajenta and acarbose in treatment of senile diabetes can effectively control the blood glucose level, and reduce the occurrence of adverse reactions such as hypoglycemia, which is worth application.
[Key words] Trajenta; Acarbose; Senile diabetes
糖尿病是一組以高血糖为特征的代谢性疾病。近年来,随着人口老龄化人群的不断增多和各种不良因素的影响,老年糖尿病的发病率也明显升高。据IDF报道显示[1-2],我国成年糖尿病患病人数达1.14亿,患病率为11.6%,其中老年糖尿病患病率占22.5%。与年轻患者相比,老年患者由于机体功能退化,往往伴随多种疾病或被其他慢性疾病所掩盖,增加了并发症和不良反应发生的风险。对老年糖尿病患者降糖治疗时,不仅要考虑药物的降糖作用,还要充分考虑药物的安全性。对该科2017年2月—2018年2月收治的67例老年糖尿病患者采用利格列汀联合阿卡波糖治疗并观察,现报道如下。
1 资料与方法
1.1 一般资料
选取该科收治的老年糖尿病患者134例为观察对象,患者均符合WHO 1999年所制定的糖尿病诊断标准[3]。随机将患者分为两组各67例,观察组男43例,女24例,年龄61~79岁,平均(68.9±2.1)岁,病程3~16年,平均(9.2±1.2)年,其中I型糖尿病11例,2型糖尿病56例,合并高血压12例,合并冠心病7例;对照组男45例,女22例,年龄62~76岁,平均(67.4±2.9)岁,病程3~16年,平均(8.7±1.4)年,其中I型糖尿病13例,2型糖尿病54例,合并高血压10例,合并冠心病8例。排除合并全身性疾病、严重肝肾功能不全及恶性肿瘤者。……
